New perspectives for the treatment of disorders of sleep and arousal

Annales Pharmaceutiques Francaises

Volumn 65, Issue 4, 2007, Pages 268-274

  Sanger, D J ^a   Soubrane, C ^a   Scatton, B ^a  

^a SANOFI   (France)

Author keywords

Arousal; GABA; Insomnia; Melatonin; Serotonin

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; AGOMELATINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; BENZODIAZEPINE DERIVATIVE; DOXEPIN; EPLIVANSERIN; EVT 201; GABAPENTIN; GABOXADOL; HY 12075; HYPNOTIC AGENT; INDIPLON; LY 156735; MELATONIN; MODAFINIL; NG 2 73; OREXIN; OXYBATE SODIUM; PREGABALIN; PRUVANSERIN; RAMELTEON; SEROTONIN AGONIST; TEMAZEPAM; TRIAZOLAM; UNCLASSIFIED DRUG; VEC 162; ZALEPLON; ZOLPIDEM; ZOPICLONE;

CIRCADIAN RHYTHM; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DISEASE ASSOCIATION; DRUG BINDING SITE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; HYPOTHALAMUS; INSOMNIA; REVIEW; SLEEP AROUSAL DISORDER; SLEEP DISORDER; SLEEP WAKING CYCLE; TREATMENT PLANNING;

EID: 34547627826     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4509(07)90046-2     Document Type: Article

References (25)

1. Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003; 26(4): 261-82.
2. Doble A. New insights into the mechanism of action of hypnotics. J Psychopharmacol 1999; 13(Suppl. 1): S11-20.
3. Sanger DJ, Depoortere H. The pharmacology and mechanism of action of zolpidem. CNS Drug Reviews 1998: 4: 323-40.
4. Bateson AN. Further potential of the GABA receptor in the treatment of insomnia. Sleep Med 2006; 7(Suppl. 1): S3-9.
5. Ebert B, Wafford KA, Deacon S. Treating insomnia: Current and investigational pharmacological approaches. Pharmacol Ther 2006; 112: 612-29.
6. Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci 2005; 6: 215-29.
7. Neubauer DN. Indiplon: the development of a new hypnotic. Expert Opin Investig Drugs 2005; 14: 1269-76.
8. Atack JR. The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Expert Opin Investig Drugs 2005; 14: 601-18.
9. Moen MD, Plosker GL. Zolpidem extended-release. CNS Drugs 2006; 20: 419-26.
10. Roth T, Soubrane C, Titeux L, Walsh JK, Zoladult Study Group. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 2006; 7: 397-406.
11. Landolt HP, Meier V, Burgess HJ, Finelli LA, Cattelin F, Achermann P et al. Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology 1999; 21: 455-66.
12. Bazil CW. Effects of antiepileptic drugs on sleep structure: are all drugs equal? CNS Drugs 2003; 17: 719-28.
13. Yanai K, Tashiro M. The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies. Pharmacol Ther 2007; 113: 1-15.
14. Navab P, Guilleminault C. Emerging pharmacotherapeutic agents for insomnia: a hypnotic panacea? Expert Opin Pharmacother 2006; 7: 1731-8.
15. Keating GM, Raffin MJ. Modafinil: a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder. CNS Drugs 2005; 19: 785-803.
16. Ballon JS, Feifel D. A systematic review of modafinil: Potential clinical uses and mechanisms of action. J Clin Psychiatry 2006; 67: 554-66.
17. Scharf MB. Sodium oxybate for narcolepsy. Expert Rev Neurother 2006; 6: 1139-46.
18. Pardi D, Black J. Gamma-hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness. CNS Drugs 2006; 20: 993-1018.
19. Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005; 9: 269-310.
20. Baumann CR, Bassetti CL. Hypocretins (orexins) and sleepwake disorders. Lancet Neurol 2005; 4(10): 673-82.
21. Zee PC, Manthena P. The brain's master circadian clock: Implications and opportunities for therapy of sleep disorders. Sleep Med Rev 2007; 11: 59-70.
22. Touitou Y, Bogdan A. Promoting adjustment of the sleepwake cycle by chronobiotics. Physiol Behav 2006; 90: 294-300.
23. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: Nature's most versatile biological signal? FEBS J 2006; 273: 2813-38.
24. McGechan A, Wellington K. Ramelteon. CNS Drugs 2005; 19: 1057-65.
25. Zupancic M, Guilleminault C. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 2006; 20: 981-92.